Table III.
The 50% inhibitory concentration of platinum and C6-ceramide alone and in combination on ovarian cancer cell lines
| Treatment Type | SKOV3 | Pt-potency Fold Enhancement | A2780 | Pt-potency Fold Enhancement | A2780cp | Pt-potency Fold Enhancement |
|---|---|---|---|---|---|---|
| Cisplatin in PBS | 18.2 ± 0.1 μM | -- | 3.6 ± 0.1 μM | -- | 96.5 ± 0.1μM | -- |
| Ceramide in DMSO | 10 ± 0.1 μM | -- | 9.6 ± 0.1μM | -- | 30 ± 2 μM | -- |
| Ceramide NE (NT) | 9.1 ± 0.1 μM | -- | 1.5 ± 0.01 μM | -- | 1.3 ± 0.02 μM | -- |
| Ceramide NE (T) | 8.3 ± 0.1 μM | -- | ND | ND | ND | -- |
| Myrisplatin NE (NT) | 5.5 ± 0.1 μM | 3.3 | 0.24 ± 0.01 μM | 15 | 0.8 ± 0.01μM | 120.6 |
| Myrisplatin NE (T) | 2.4 ± 0.1μM | 7.6 | 0.42 ± 0.01 μM | 8.6 | ND | ND |
| Myrisplatin/ceramide NE (NT) | 0.46 ± 0.01 μM | 39.6 | 0.16 ± 0.01 μM | 22.5 | 0.4 ± 0.02 μM | 241.3 |
| Myrisplatin/ceramide NE (T) | 0.36 ± 0.01 μM | 50.5 | ND | ND | l.l ± 0.01μM | 87.7 |
- A2780 & A2780CP cells do not express EGFR, thus IC50 not determined (ND) for targeted systems.
- In case of combination treatment, platinum to ceramide molar ratio was 1:5 in the formulation